052260.KQ HYUNDAI BIOLAND Co.Ltd
- Market cap
- KRW 122B
- P/E
- -
- P/B
- 0.84x
- ROE
- 15.4%
- Dividend yield
- 1.72%
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 052260.KQ undervalued?
Graham numberThe Graham number of HYUNDAI BIOLAND Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HYUNDAI BIOLAND Co.Ltd fundamental analysis
9 of 22 checks passedROE 1/2
Moderate return on equity (15.4%), between 10% and 20%.
ROA 1/1
Return on assets (13.4%) is above the industry median (1.3%).
Profit Consistency 1/2
Profitable for 4 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-95.6%) is below the industry median (-73.4%).
Revenue Growth 1/2
Revenue grew 9.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (0.8x) is above the industry median (0.7x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (1.7%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
Payout ratio is 831.3%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
HYUNDAI BIOLAND Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HYUNDAI BIOLAND Co.Ltd
HYUNDAI BIOLAND Co.,Ltd manufactures and sells raw materials for cosmetics, nutraceuticals, and regenerative medicines. It offers anti-aging, moisturizing, whitening, skin protection, and other cosmetic ingredients; functional food ingredients and general food raw materials; and active pharmaceutical ingredients. The company was formerly known as SKbioland Co., Ltd. and changed its name to HYUNDAI BIOLAND Co.,Ltd in October 2020. HYUNDAI BIOLAND Co.,Ltd was incorporated in 1…
Full company profileHYUNDAI BIOLAND Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HYUNDAI BIOLAND Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 97.8B | 103B | 101B | 106B | 88.9B | 103B | 99.2B | 96.7B | 120B | 131B | 157B |
| Gross Profit | 38.4B | 37.2B | 40.6B | 39.3B | 17.3B | 37.3B | 35.6B | 39.8B | 52.8B | 53.5B | 66.9B |
| Operating Income | 16.0B | 16.1B | 16.7B | 14.0B | -16.9B | -13.6B | 7.38B | 15.0B | 13.5B | 12.8B | 24.5B |
| EBITDA | - | - | - | - | - | - | 14.4B | 24.3B | 22.9B | 17.7B | 29.8B |
| Net Income | 12.4B | 12.0B | 15.0B | 10.8B | -13.5B | -11.7B | 4.76B | 8.06B | 5.70B | 253M | 22.3B |
| EPS | 828 | 799 | 1,003 | 723 | -903 | -779 | 318 | 269 | 190 | 8.42 | 745 |
| Balance Sheet | |||||||||||
| Total Assets | 168B | 176B | 193B | 209B | 188B | 173B | 176B | 184B | 195B | 167B | 166B |
| Total Liabilities | 37.1B | 38.6B | 44.3B | 53.3B | 50.4B | 47.4B | 46.8B | 48.1B | 56.7B | 30.7B | 20.7B |
| Shareholders' Equity | 131B | 138B | 149B | 156B | 137B | 125B | 129B | 136B | 138B | 136B | 146B |
| Cash & Short-term Investments | 25.1B | 19.0B | 20.5B | 14.3B | 10.4B | 14.7B | 23.1B | 23.1B | 26.0B | 17.8B | 8.89B |
| Total Debt | 21.5B | 23.7B | 19.3B | 32.0B | 26.9B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.8B | 14.0B | 15.9B | 11.4B | 8.96B | 21.5B | 11.3B | 5.59B | 4.60B | 19.5B | 19.4B |
| Capital Expenditure | 14.6B | 16.3B | 12.8B | 16.0B | 6.04B | 2.26B | 4.75B | 6.29B | 3.92B | 4.07B | 2.50B |
| Free Cash Flow | - | - | - | - | 1.37B | 18.1B | 6.56B | -703M | 676M | 15.4B | 16.9B |
| Ratios | |||||||||||
| ROE | 9.5% | 8.7% | 10.1% | 7.0% | -9.9% | -9.3% | 3.7% | 5.9% | 4.1% | 0.2% | 15.4% |
| ROA | 7.4% | 6.8% | 7.8% | 5.2% | -7.2% | -6.8% | 2.7% | 4.4% | 2.9% | 0.2% | 13.4% |
| Net Profit Margin | 12.7% | 11.7% | 15.0% | 10.2% | -15.2% | -11.4% | 4.8% | 8.3% | 4.8% | 0.2% | 14.2% |
| Debt to Equity | 0.16x | 0.17x | 0.13x | 0.21x | 0.20x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HYUNDAI BIOLAND Co.Ltd dividends
- Dividend yield
- 1.72%
- Forward dividend
- -
- Payout ratio
- 831.3%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 2.10B | 70 | 831.3% |
| 2024 | KRW 1.05B | 35 | 18.4% |
| 2023 | KRW 1.05B | 35 | 13.0% |
| 2022 | KRW 1.05B | 70 | 22.0% |
| 2021 | KRW 1.50B | 100 | - |
| 2020 | KRW 5.25B | 350 | - |
| 2019 | KRW 4.50B | 300 | 41.5% |
| 2018 | KRW 3.75B | 250 | 24.9% |
| 2017 | KRW 3.75B | 250 | 31.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on May 17, 2024.
Who owns HYUNDAI BIOLAND Co.Ltd
- Insiders 35.00%
- Institutions 6.10%
- Public & others 58.90%
- Shares outstanding 15.0M
- Free float 9.75M
HYUNDAI BIOLAND Co.Ltd company profile
- Company name
- HYUNDAI BIOLAND Co.Ltd
- Ticker
- 052260.KQ
- ISIN
- KR7052260007
- Exchange
- KOSDAQ
- Sector
- Consumer Non-Cyclicals
- Industry
- Personal Care Products
- Fiscal year end
- December
- Address
- 22, Osongsaengmyeong 2-ro, Cheongju, South Korea
- Phone
- 82 4 3249 6720
- Website
- hyundaibioland.co.kr
About HYUNDAI BIOLAND Co.Ltd
HYUNDAI BIOLAND Co.,Ltd manufactures and sells raw materials for cosmetics, nutraceuticals, and regenerative medicines. It offers anti-aging, moisturizing, whitening, skin protection, and other cosmetic ingredients; functional food ingredients and general food raw materials; and active pharmaceutical ingredients. The company was formerly known as SKbioland Co., Ltd. and changed its name to HYUNDAI BIOLAND Co.,Ltd in October 2020. HYUNDAI BIOLAND Co.,Ltd was incorporated in 1995 and is based in Cheongju, South Korea.
HYUNDAI BIOLAND Co.Ltd management
2- Mr. Chan-Bok JeongChairman and Chief Exec. Officer · born 1956
- In-Kuk ImVP and Director · born 1960